The Medicines Company Submits Angiomax (Bivalirudin) sNDA to Expand Label to Include ACUITY Data

The Medicines Company announced it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for Angiomax (bivalirudin) in support of a proposed new dosage for immediate treatment of patients with acute coronary syndromes (ACS).
Business Wire